Iodine-131 Anti-B1 Antibody

PreclinicalRadiopharmaceutical

GSK

Iodine-131 Anti-B1 Antibody is one of 6 biologic programs targeting Antibody. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AntibodyUnknown status

AntibodyPreclinical

Unknown status

Competition

Competitive Landscape

7 competitors in Antibody

#DrugCompanyPhaseTrials

BEYFORTUS

Sanofi

Phase 3

1 2

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 2

2 3

Sylvant

RRECORDATI GROUP

Phase 1

1 4

CID-103

CCASI Pharmaceuticals, Inc.

Preclinical

1 5

Iodine-131 Anti-B1 Antibody

GSK

Preclinical

1 6

Gammaglobulin

UUniversity of Aarhus

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma3 trials

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

Completed· GSK logo

GSK·Phase 1·NCT00992758·11 enrolled

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Unknown status·CCorixa Corporation·Phase 2·NCT00022932

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Unknown status·CCorixa Corporation·N/A·NCT00022893

Chronic Lymphocytic Leukemia1 trial

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Unknown status·CCorixa Corporation·Phase 1·NCT00022880·30 enrolled

Antibody1 trial

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Unknown status·CCorixa Corporation·N/A·NCT00022958

Safety and Efficacy1 trial

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Unknown status·CCorixa Corporation·Phase 1·NCT00022906·24 enrolled

Mantle Cell Lymphoma1 trial

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Completed·CCorixa Corporation·Phase 2·NCT00022945

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Iodine-131 Anti-B1 Antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iodine-131 Anti-B1 Antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iodine-131 Anti-B1 Antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Preclinical[1]
Company: GSK

Iodine-131 Anti-B1 Antibody

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma3 trials

Chronic Lymphocytic Leukemia1 trial

Antibody1 trial

Safety and Efficacy1 trial

Mantle Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News